Aldeyra Therapeutics to Host Investor Roundtable Q&A
Aldeyra Therapeutics (Nasdaq: ALDX) will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024, at 8:00 a.m. ET.
This event will feature remarks from Todd C. Brady, M.D., Ph.D., President and CEO, followed by a Q&A session. Shareholders and prospective investors can submit questions via the webcast portal during the event or ahead of time by email starting Monday, June 17.
The live audio webcast and slide presentation will be accessible on the Aldeyra website, with a replay available for 90 days.
- Hosting an Investor Roundtable Q&A can increase transparency and investor confidence.
- Opportunity for shareholders and prospective investors to interact directly with the CEO.
- The event features a live audio webcast and slide presentation, enhancing accessibility.
- Replay availability for 90 days provides extended access to the event's content.
- No new financial data or clinical trial results are mentioned in the PR.
- Potential for unanswered or unsatisfactory responses during the Q&A, which could lead to investor dissatisfaction.
Event Scheduled for Thursday, June 20 at 8:00 a.m. ET
The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session. The call will be open to all current and prospective Aldeyra shareholders, and participants will be able to submit questions through the webcast portal during the event. In addition, beginning Monday, June 17, investors will be able to submit questions ahead of the call via email to investorrelations@aldeyra.com.
A live audio webcast and slide presentation will be accessible from the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com/. A replay will be available for 90 days following the event.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
FAQ
When is Aldeyra Therapeutics' Investor Roundtable Q&A scheduled?
Where can I access the Aldeyra Therapeutics Investor Roundtable webcast?
Can shareholders submit questions for the Aldeyra Therapeutics Investor Roundtable Q&A?
Who will be presenting at the Aldeyra Therapeutics Investor Roundtable?
Will there be a replay available for the Aldeyra Therapeutics Investor Roundtable Q&A?
